CAROLE BEN-MAIMON
CIK 1529611 · President and CEO · last filed 2026-01-27
CAROLE BEN-MAIMON is a President and CEO who has filed 30 SEC Form 4 insider transactions across 3 companies since 2011. The most recent filing, for LRMR, was dated Jan 27, 2026. Across all open-market trades the lifetime net is +$118.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.39M
3
30
$118.5K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LRMR | President and CEO | 399,432 | $3.47 | $1.39M | $118.5K | 11 | 2026-01-27 |
| Teligent, Inc. (TLGT) Delisted | Director | — | $0.17 | — | $0 | 2 | 2021-07-22 |
| Impax Laboratories, LLC (IPXL) Delisted | President, Global Pharm. | 62,914 | — | — | $0 | 7 | 2013-10-28 |
Recent Filings
30 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-27 | LRMR | Grant (A) | +100,100 | $0 | EDGAR |
| 2025-01-24 | LRMR | Grant (A) | +91,000 | $0 | EDGAR |
| 2024-01-19 | LRMR | Grant (A) | +66,125 | $0 | EDGAR |
| 2023-05-18 | LRMR | Buy (P) | +5,000 | $18.5K | EDGAR |
| 2023-02-02 | LRMR | Grant (A) | +205,000 | $0 | EDGAR |
| 2022-09-19 | LRMR | Buy (P) | +31,746 | $100.0K | EDGAR |
| 2022-05-12 | LRMR | Grant (A) | — | $0 | EDGAR |
| 2022-01-20 | LRMR | Grant (A) | — | $0 | EDGAR |
| 2021-07-22 | Teligent, Inc. (TLGT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-21 | LRMR | Grant (A) | — | $0 | EDGAR |